Evercore ISI analyst Joshua Schimmer maintained a Buy rating on Denali Therapeutics (NASDAQ:DNLI) on Friday, setting a price target of $111, which is approximately 101.74% above...
Jefferies (NYSE:JEF) analyst Michael Yee maintained a Buy rating on Denali Therapeutics (NASDAQ:DNLI) on Sunday, setting a price target of $95, which is approximately 48.67%...
Creating A New Standard For Treating CNS DiseaseInhibikase Therapeutics (NASDAQ:IKT) is a biotechnology company focused on creating new therapies for Central Nervous System (CNS)...
Biogen, Inc. BIIB announced that a phase II/III study evaluating cotoretigene toliparvovec (BIIB112), a gene therapy for treating patients with X-linked retinitis pigmentosa...
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company clinical programs include leucine-rich repeat kinase 2 (LRRK2) inhibitor program, eukaryotic initiation factor 2 B (EIF2B) activator program, enzyme transport vehicle: iduronate 2-sulfatase (ETV:IDS) program, receptor interacting serine/threonine protein kinase 1 (RIPK1) inhibitor program and second non-CNS penetrant RIPK1 inhibitor. The Company engineers its product candidates to cross the blood-brain barrier (BBB), and act directly in the brain. Its pipeline includes approximately 15 programs that are based on its TV technology, including the lead program ETV:IDS (DNL310). Its product pipeline includes DNL151, DNL593 (PTV:PGRN), DNL126 (ETV:SGSH), DNL919 (ATV:TREM2), DNL788, DNL343, DNL758 and others.
|Average||63.21 (+100.87% Upside)|
|No. of Analysts||14|